IRulya Therapeutics Stock (NASDAQ:IRLA)
Previous Close
$34.45
52W Range
$15.10 - $910.00
50D Avg
$30.92
200D Avg
$78.84
Market Cap
$39.00M
Avg Vol (3M)
$29.74K
Beta
1.33
Div Yield
-
IRLA Company Profile
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.